400613-89-0Relevant articles and documents
CuBr2-catalyzed ring opening/formylation reaction of cyclopropyl carbinols with DMF to synthesize formate esters
Zhuang, Daijiao,Gatera, Tharcisse,Yan, Rulong
supporting information, (2020/10/19)
An unprecedented protocol for the synthesis of formate esters has been developed by employing N,N-dimethylformamide (DMF) as both the source of CHO and solvent. This reaction undergoes ring opening of the cyclopropyl carbinols and in situ formation of homoallylic alcohols, which reacts with DMF to give the desired products. The substrate cyclopropyl carbinols with different groups participate smoothly in this process and the desired products are obtained in moderate to good yields.
Calcium receptor antagonist
-
Page 19-20, (2010/11/30)
A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.
